The Max Foundation Delivers First Treatment into Mozambique

The Max Foundation Delivers First Treatment into Mozambique

On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

“The Max Access Solutions provides hope in the form of innovative cancer treatment in neglected regions of the world,” says Pat Garcia-Gonzalez, CEO of The Max Foundation. “Today we reached a new frontier and I am deeply grateful to all who made it possible.”

In the beginning of 2018, Cathy Scheepers, The Max Foundation’s Region Head of Africa & Middle East visited the hospital in Maputo and learned of over 100 chronic myeloid leukemia (CML) patients who were unable to access treatment. The only way patients could access treatment was to travel to South Africa, a challenging day of travel. Mozambique is one of the poorest countries in the world, and for the majority of people living there, traveling to find treatment was simply not an option.

“Over 100 patients who have had a five-year life expectancy now have access to live normal lives.” says Cathy. “We’re changing not only the physician and patient perspectives, but also the broader community perspective that cancer is not always a death sentence. There is hope if you have access to treatment.”

Thank you to all who made access to treatment in Mozambique a reality: the passionate donors, physicians in Maputo, Humanitarian PACT partner Novartis, advisors, and The Max Foundation’s global team members. Everyone involved worked tirelessly to expand the scope of Max Access Solutions into the hands of those awaiting treatment, and now, patients have the chance to spend more days with their families, communities, and loved ones.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….

  • Spot On CML Grows in the Philippines

    Spot On CML Grows in the Philippines

    Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.